Longevity medicine has attracted intense attention from physicians, patients, and even investors over the past year.

Longevity medicine represents a fundamental shift in medicine from reacting to the consequences of aging and disease to one where the aim is to optimize and even reverse aging.

In this video, BrainKey’s CEO, neuroscientist Dr. Owen Phillips, Ph.D. discusses longevity with the multitalented, Dr. Dina Radenkovic, MD, Partner at the SALT Bio Fund and Chief Science Officer of the Hooke longevity clinic.

Dina Radenkovic - Dina is an academic doctor and medical technology entrepreneur, working in the computational biology of aging.  She is a Partner at the Programmable Biology SALT Fund. She is a co-founder & Chief Science Officer Hooke, an elite longevity research clinic in London launched in partnership with Dr. Eric Verdin from the Buck Institute for Research on Aging. She is also a senior scientist at the Buck Artificial Intelligence applied to the Biology of Aging Platform where they study novel biomarkers of biological aging.

Dina qualified with a dual degree in medicine and physiology from UCL Medical School, with the elective at the New England Journal of Medicine, Harvard University, awarded number one in preclinical medicine and the best overall performance in physiology BSc. She has led two projects, a digital therapeutics company for women and an algorithm for cardiac MRI to major industry acquisitions. She later worked as Research Fellow at King's College London and at Harvard University. Dina did her residency at St Thomas’ Hospital in London. She has over 30 academic papers, 7 grants, and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages.